EP1075184A4 - Compositions et procedes de vaccination active - Google Patents

Compositions et procedes de vaccination active

Info

Publication number
EP1075184A4
EP1075184A4 EP99921790A EP99921790A EP1075184A4 EP 1075184 A4 EP1075184 A4 EP 1075184A4 EP 99921790 A EP99921790 A EP 99921790A EP 99921790 A EP99921790 A EP 99921790A EP 1075184 A4 EP1075184 A4 EP 1075184A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
active vaccination
vaccination
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99921790A
Other languages
German (de)
English (en)
Other versions
EP1075184A1 (fr
Inventor
David B Agus
David Scheinberg
Wendy Roberts
Andrew D Zelenetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of EP1075184A1 publication Critical patent/EP1075184A1/fr
Publication of EP1075184A4 publication Critical patent/EP1075184A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
EP99921790A 1998-05-08 1999-05-07 Compositions et procedes de vaccination active Withdrawn EP1075184A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8487098P 1998-05-08 1998-05-08
US84870P 1998-05-08
PCT/US1999/010065 WO1999057981A1 (fr) 1998-05-08 1999-05-07 Compositions et procedes de vaccination active

Publications (2)

Publication Number Publication Date
EP1075184A1 EP1075184A1 (fr) 2001-02-14
EP1075184A4 true EP1075184A4 (fr) 2002-01-30

Family

ID=22187732

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99921790A Withdrawn EP1075184A4 (fr) 1998-05-08 1999-05-07 Compositions et procedes de vaccination active

Country Status (4)

Country Link
EP (1) EP1075184A4 (fr)
JP (1) JP2002514573A (fr)
CA (1) CA2330212A1 (fr)
WO (1) WO1999057981A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
WO2001078766A1 (fr) 2000-04-13 2001-10-25 Bio Life Science Forschungs Und Entwicklungsgesellschaft Mbh Vaccin contre des maladies cancereuses, a base de mimotopes d'antigenes exprimes sur des cellules tumorales
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US20020193329A1 (en) * 2000-08-14 2002-12-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
EP1236740B1 (fr) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vaccin contre cancers associés à l'oncogène HER-2/neu
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
AU2003298984A1 (en) * 2002-12-27 2004-08-23 Shenzhen Tsinghua Yuanxing Bio-Pharm Science And Technology Co., Ltd. Method of preparing a vaccine and anti-tumor vaccines
US7812116B2 (en) * 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
US20060018911A1 (en) * 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO9957981A1 *
SHAN DAMING ET AL: "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.", BLOOD, vol. 91, no. 5, 1 March 1998 (1998-03-01), pages 1644 - 1652, XP002182861, ISSN: 0006-4971 *
ZHANG SHENGLE ET AL: "Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.", CANCER RESEARCH, vol. 56, no. 14, 1996, pages 3315 - 3319, XP002097413, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO1999057981A1 (fr) 1999-11-18
JP2002514573A (ja) 2002-05-21
CA2330212A1 (fr) 1999-11-18
EP1075184A1 (fr) 2001-02-14

Similar Documents

Publication Publication Date Title
EP1176948A4 (fr) Compositions et methodes antinauseeuses
GB9806456D0 (en) Vaccine composition
HUP0101804A3 (en) Adjuvant composition and methods for its use
GB2348808B (en) Methods and compositions for desensitisation
PL343021A1 (en) Formulations
EP1107735A4 (fr) Formulation d'omeprazole
IL138605A0 (en) Fizzy formulations
EP1056456A4 (fr) Compositions et procedes d'utilisation du r-lansoprazole
GB9819979D0 (en) Sanitising compositions and methods
AU5565099A (en) Pharmaceutical compositions and methods for use
IL143423A0 (en) Insecticidal compositions and insecticidal methods
EP1056457A4 (fr) Compositions de s-lansoprazole et procedes d'utilisation
EP1075184A4 (fr) Compositions et procedes de vaccination active
PL332616A1 (en) Hydoxymethylhexanones as odorising and savourising agents
EP1113815A4 (fr) Compositions immunogenes et leurs utilisations
EP1073333A4 (fr) Compositions a base de s-rabeprazole et procedes
EP1139981A4 (fr) Compositions et procedes d'utilisation associes
GB9801870D0 (en) Vaccine composition
GB0318112D0 (en) ›-Secretase enzyme compositions and methods
AU2880699A (en) Pharmaceutical compositions and methods for use
AUPO982097A0 (en) Methods and compositions for use therein
GB9815002D0 (en) Formulations
EP1073332A4 (fr) Compositions a base de r-rabeprazole et procedes
EP1071325A4 (fr) Compositions et methodes de vaccination specifique de l'antigene
GB9815001D0 (en) Formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE DK ES FR GB IT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 37/18 A, 7A 61K 39/00 B, 7A 61K 39/385 B, 7A 61P 35/00 B, 7C 07K 14/705 -

A4 Supplementary search report drawn up and despatched

Effective date: 20011218

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE DK ES FR GB IT SE

17Q First examination report despatched

Effective date: 20020927

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: METHOD FOR ACTIVE VACCINATION AGASINT CD20

RTI1 Title (correction)

Free format text: METHOD FOR ACTIVE VACCINATION AGAINST CD20

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061201